Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 15/20 | 0.70 |
| ▸ | FOLR1 | P15328 | 5/20 | 0.70 |
| ▸ | SLC19A1 | P41440 | 5/20 | 0.70 |
| ▸ | SLC46A1 | Q96NT5 | 5/20 | 0.70 |
| ▸ | DHFR | P00374 | 2/20 | 0.70 |
| ▸ | GART | P22102 | 2/20 | 0.70 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.70 |
| ▸ | ATIC | P31939 | 1/20 | 0.70 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.70 |
| ▸ | FRK | P42685 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12905188 | 0.90 | TYMS (0.59) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL24629271 | 0.89 | TYMS (0.61) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL12905859 | 0.88 | TYMS (0.59) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL20908952 | 0.87 | TYMS (0.56) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL20386836 | 0.87 | TYMS (0.56) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL26019440 | 0.86 | TYMS (0.55) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL13508147 | 0.85 | TYMS (0.55) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL2260428 | 0.83 | TYMS (0.69) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL21558064 | 0.83 | TYMS (0.53) | TYMSFOLR1SLC19A1SLC46A1DHFR | |
| SCHEMBL13524779 | 0.83 | TYMS (0.67) | TYMSFOLR1SLC19A1SLC46A1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | EMPHASCIENCE, INC. | 2023-06-29 | — | — | US | disclosed |
| US-11078214-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3738594-A1 | TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020222151-A1 | A STABLE, READY TO USE AQUEOUS PHARMACEUTICAL COMPOSITION OF PEMETREXED | INTAS PHARMACEUTICALS LTD. (IN) | 2020-11-05 | — | — | WO | disclosed |
| US-10774090-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3035938-B1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3021849-B1 | NOVEL CRYSTALLINE FORMS OF PEMETREXED TROMETHAMINE SALTS | Dr Reddys Laboratories Ltd (IN) | 2019-10-09 | — | — | EP | disclosed |
| US-20190233432-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-01 | — | — | US | disclosed |
| US-9994586-B2 | Monocyclic, thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-06-12 | — | — | US | disclosed |
| WO-2018096853-A1 | NOVEL MEDOXOMIL AND HEMIACETAL ESTERS OF PEMETREXED, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING ESTER PRODRUG | 学校法人近畿大学 | 2018-05-31 | — | — | WO | disclosed |
| EP-2326351-B1 | CONJUGATES OF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9688690-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170050978-A1 | Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-02-23 | — | — | US | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233432-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | TYMS 5/4885FOLR1 243/4885SLC19A1 134/4885 |
| US-10774090-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | TYMS 5/4885FOLR1 243/4885SLC19A1 134/4885 |
| US-11078214-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DPYD, TYMS, THPO | TYMS 2/4885FOLR1 54/4885SLC19A1 93/4885 |
| US-20170050978-A1 | Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same | CYP4F3, TYMS, DPYD | TYMS 2/4885FOLR1 60/4885SLC19A1 226/4885 |
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | DHFR, MTHFD1, OAT | TYMS 18/4885FOLR1 9/4885SLC19A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.